anti-huLR C15 ADC ABBV-085, PR-1498487-MMAE PR-1498487 PAB-MMAE Developer AbbVie, Inc. Clinical domain Oncology Clinical indication Solid tumors in which huLRRC15 is expressed in the tumor stromal microenvironment. Development status Phase I A phase I an open-label dose escalation study designe...
16 - ABBV-085 is a novel antibody–drug conjugate (ADC) that targets LRRC15 in the tumor microenvironmentdoi:10.1016/S0959-8049(16)32622-3SDOSEuropean Journal of Cancer